Home/News & Insight

News & Analysis Details

Evaluate News & Events

「EVALUATEPHARMA®ワールドプレビュー2017 2022年への 望」日本語版リリースのお知らせ

Worldwide Medtech Sales Forecast to Reach $522 Billion by 2022 with a CAGR of 5.1% between 2016 and 2022

Biopharma stages a strong recovery over the first half of 2017, while unprecedented amounts of money flow in medtech

Japanese Pharmaceutical Market Set to Grow 3.3% (CAGR) Between 2017 and 2022, Significantly Lower than the Worldwide Outlook (6.5% CAGR)

Epi Analyzer: Blockbusters Out, Highly Targeted Therapies In

Pricing pressure causes worldwide drug sales forecasts to fall for first time in 10 years

New EP Vantage Report Sees Immuno-oncology Trials Triple and Keytruda Steal the Crown from Opdivo

Median Cost Per Patient for Orphan Drugs is 5.5 Times Higher Than Non-Orphan Drugs

2016 leaves pharma facing stormy waters, while the medtech sector faces an innovation imperative

The Value of Outliers in Consensus Forecasting: A perspective on the portfolio strategy of the top 20 pharma companies

Higher M&A Activity and Investor Cash Expected to Re-invigorate Pharma and Biotech in 2017

Evaluate Ltd Receives Significant Investment from HgCapital to Expand Products and Services

Worldwide Medtech Sales Forecast to Reach $529.8 Billion by 2022

Worldwide Prescription Drug Sales Forecast to Grow 6.3% Annually

Pharma and Medtech Sectors Struggle in First Half of 2016

European Pharmaceutical Market Projected to Grow from € 169 Billion in 2015 to € 206 Billion in 2022; CAGR of 3.2 Percent Between 2015 - 2022

LISTEN: Jon Gardner, Deputy News Editor for EP Vantage, talks to Dan Levine of The Bio Report about the ASCO meeting, what the early abstracts say, and who will likely be making headlines at this year’s meeting.

Industry on the brink of first CAR-T approval, but big obstacles remain, says EP Vantage

EP Vantage Releases its Annual Analysis of Pharma & Biotech and Medtech Sector Performance: 2015 in Review Reports

Evaluate Bolsters Custom Services Capabilities to Meet Growing Demand for Expert Analytical and Data Services

Blockbuster Launches and Limited Impact of US Biosimilar Entrants Sustain Biopharma’s Momentum in 2016

「EVALUATEPHARMA®ワールドプレビュー2015 2020 年への展望」日本語版リリースのお知らせ製薬およびバイオテクノロジー業界への信頼感が継続製薬業界の研究開発パイプラインの価値は 18%増加して4,930 億ドルに達し、売上は年間 4.8%の成長の見込み

PD-1/PD-L1 Combinations Drive the Development of New Immunotherapies

Per Patient Costs for Orphan Drugs is 13.8 Times Higher Than Non-Orphan Drugs

AdvaMed Works with Evaluate to Provide AdvaMed Members Strategic Insights via EvaluateMedTech

Worldwide Medtech Sales Forecast to Reach $477.5 Billion by 2020

Big Changes for Medtech in First Half of 2015 While Pharma Set To Break Records

Medtech Jobs Jump Thanks To Mergers, Biotech Has Most Efficient Employees

Evaluate and BIA's UK Biotech: A 10 Year Horizon - 2014 and 2015 Setting New Records in UK Biotech Financing via Capital Markets and Venture Capital

Pharma R&D Pipeline Value Jumps 18 Percent to $493 Billion, Drug Sales Forecast to Grow Nearly Five Percent Annually

Pharma Sales Forecast to Grow 5% Annually Through to 2020, Industry's R&D Pipeline Valued at $493bn

EP Vantage レポート 「製薬・バイオテクレビュー2014」
日本語版リリースのお知らせ2014年の
M&A取引総額が記録的な2,120億ドルを達成

SIGN UP: Evaluate Market Movers & Shakers Free Monthly Newsletter

Evaluate Ltd and AdverseEvents, Inc. Team Up to Create New Insight on FDA Adverse Event Reporting

Megamergers Dominate MedTech Industry in 2014 with Nearly $40 Billion in Deals

Pharma & Biotech M&A Deals Reached Record $212 Billion in 2014

Five Year Peak Sales Forecast of Newly Reimbursed Drugs in Japan Surges to $34bn

New EP Vantage report shows investor enthusiasm for cancer-fighting CAR-T therapies is likely to continue despite risks

Innovation Driving Positive Outlook for Pharma and Biotech in 2015

New Report Shows Orphan Drug Market to Reach $176 Billion by 2020

Medtech Market to Achieve Global Sales of $514 Billion by 2020; Megamergers Set to Reshuffle Top Players

Top 100 US Drug Pricing Median Jumps Seven-Fold to $9,400 in 2014

COO Alexander Karle appointed CEO of Evaluate Ltd

Mood Lifts for Medtech in First Half of 2014 While Pharma Sector Faces New Struggles

Medtech Industry Employment Up for Large and Small Firms in 2013

Evaluate Founder and CEO Receives PharmaVOICE 100 Award

Worldwide Prescription Drug Sales to Exceed Trillion Dollar Mark by 2020

Big Pharma Becomes a Smaller Employer While Biotech Booms

Sovaldi Forecast to be Biggest Selling Drug in 2020 as EvaluatePharma Extends Consensus Sales Forecasts

Record-Breaking Valuations and Surging Share Prices Drive Strong Pharma and Biotech Sector Performance in 2013

M&A Slowdown and Drop in FDA Approvals Stifles Growth of Medtech Sector in 2013

Absence of Blockbuster Drug Launches in 2014 Puts R&D Productivity at Risk

FDA Grants 37 Breakthrough Designations in 2013

2013 FDA Approval Rates Suggest Record Year for Post-Launch Success 

Evaluate Ltd. Launches Innovative Life Sciences Market Assessment Solution for Healthcare Decision Makers

Medtech Sales Forecast to Reach US$455 Billion by 2018 23 Sept 2013

Return to Growth for Pharmaceutical Sector World Preview 2013 Outlook to 2018 24 June 2013

Press Advisory - Evaluate to launch Word Preview 2013 Edition at DIA

BIO 2013: Anthony Raeside, Head of Research on Orphan Drug Report 2013

Meet us at these Events 

Buzz - Evaluate in the press, industry reports and more

More press releases

Evaluate Reports

Japanese Edition: EvaluatePharma World Preview 2017, Outlook to 2022

EvaluateMedTech World Preview 2017, Outlook to 2022

EP Vantage Pharma & Biotech Half-Year Review 2017

EP Vantage Medtech Half-Year Review 2017

Unlocking the Value of Epidemiology Data for Improved Portfolio Decision Making

EvaluatePharma World Preview 2017, Outlook to 2022 Report

EP Vantage PD-1/PD-L1 Combination Therapies 2017 Report

EvaluatePharma Orphan Drug 2017 Report

EP Vantage Pharma & Biotech 2016 in Review

EP Vantage Medtech 2016 in Review

Evaluate Forecasting Excellence: The Value of Outliers in Consensus Forecasting

EP Vantage 2017 Preview

EP Vantage Brexit: Laying Out a Plan for UK Healthcare

EvaluateMedTech World Preview 2016, Outlook to 2022

EvaluatePharma World Preview 2016, Outlook to 2022

EP Vantage Pharma & Biotech Half-Year Review 2016

EP Vantage Medtech Half-Year Review 2016

Pharmaceutical Innovation in Europe

EP Vantage Shifting CAR-Ts Into a Higher Gear

EP Vantage 2016 ASCO Backgrounder

EP Vantage Pharma & Biotech 2015 in Review

EP Vantage Medtech 2015 in Review

EVALUATE CUSTOM SERVICES: Data-driven solutions customised to your specific business challenges - FIND OUT MORE

EP Vantage Pharma & Biotech 2016 Preview

Japanese Edition: EvaluatePharma World Preview 2015, Outlook to 2020

EP Vantage PD-1/PD-L1 Combination Therapies

EvaluatePharma Orphan Drug Report 2015

EvaluateMedTech World Preview 2015, Outlook to 2020

EP Vantage Pharma & Biotech Half-Year Review 2015

EP Vantage Medtech Half-Year Review 2015

INFOGRAPHIC: Brazil Market Landscape

EP Vantage Report: Fewer, but bigger: medtech jobs jump thanks to mergers

EP Vantage Report: Mid-tier players make the most efficient employers

Evaluate and BIA's UK Biotech: A 10 Year Horizon

EvaluatePharma World Preview 2015, Outlook to 2020

Japanese Edition: EP Vantage Pharma & Biotech 2014 in Review

EvaluatePharma Optimising Clinical Trial Strategy by Analysing Marketed Drugs Adverse Events

EP Vantage MedTech 2014 in Review

EP Vantage Pharma & Biotech 2014 in Review

EvaluatePharma Japan Sales, Volume, Pricing 2015

EP Vantage Not for the Faint of CAR-T: The CAR-T Therapy Landscape in 2015

EP Vantage Pharma & Biotech 2015 Preview

Japanese Edition: EvaluatePharma World Preview 2014, Outlook to 2020

EvaluatePharma Orphan Drug Report 2014

EP Vantage Most Valuable R&D Assets

EvaluateMedTech World Preview 2014, Outlook to 2020

EvaluatePharma Budget-busters: The shift to high-priced innovator drugs in the USA

EP Vantage Pharma & Biotech Half-Year Review 2014

EP Vantage Medtech Half-Year Review 2014

EvaluatePharma World Preview 2014, Outlook to 2020

EvaluatePharma Pharmaceutical & Biotech Sales Analysis by Country

EP Vantage Pharma & Biotech 2013 in Review

EP Vantage Medtech 2013 in Review

EP Vantage Biggest Launches 2014

EP Vantage A Breakthrough Year for Unmet Diseases

EP Vantage FDA Approval Rates 2013

EvaluateMedTech World Preview 2013 Outlook to 2018: The Future of Medtech

EP Vantage Pharma Half -Year Review 2013

EP Vantage Medtech Half -Year Review 2013

EvaluatePharma World Preview 2013 Outlook to 2018 Returning to Growth

EvaluatePharma Orphan Drug Report 2013

EP Vantage Biotech & Pharma 2012 Year in Review

EvaluatePharma NASDAQ Biotech Index Up Close 2012